Free Trial
→ Bezos… DOOMED (From Paradigm Press) (Ad)tc pixel Free IBT Stock Alerts

International Biotechnology (IBT) Competitors

International Biotechnology logo
GBX 1,015 -10.00 (-0.98%)
As of 05:09 AM Eastern
Compare

IBT vs. TMPL, JFJ, IHP, WWH, and GROW

Should you buy International Biotechnology stock or one of its competitors? International Biotechnology's main competitors and comparable companies include Temple Bar (TMPL), JPMorgan Japanese (JFJ), IntegraFin (IHP), Worldwide Healthcare (WWH), and Molten Ventures (GROW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "asset management & custody banks" industry.

How does International Biotechnology compare to Temple Bar?

International Biotechnology (LON:IBT) and Temple Bar (LON:TMPL) are both small-cap finance companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation.

International Biotechnology has a beta of 0.461, meaning that its share price is 54% less volatile than the broader market. Comparatively, Temple Bar has a beta of 1.147, meaning that its share price is 15% more volatile than the broader market.

International Biotechnology has a net margin of 82.27% compared to Temple Bar's net margin of 74.06%. International Biotechnology's return on equity of 27.35% beat Temple Bar's return on equity.

Company Net Margins Return on Equity Return on Assets
International Biotechnology82.27% 27.35% 3.57%
Temple Bar 74.06%19.52%7.08%

Temple Bar has higher revenue and earnings than International Biotechnology. International Biotechnology is trading at a lower price-to-earnings ratio than Temple Bar, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
International Biotechnology£78.01M4.12£37.91M£241.734.20
Temple Bar£222.42M5.95£154.90M£75.205.73

6.7% of International Biotechnology shares are owned by institutional investors. Comparatively, 10.7% of Temple Bar shares are owned by institutional investors. 1.1% of International Biotechnology shares are owned by insiders. Comparatively, 0.4% of Temple Bar shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, International Biotechnology had 1 more articles in the media than Temple Bar. MarketBeat recorded 1 mentions for International Biotechnology and 0 mentions for Temple Bar. International Biotechnology's average media sentiment score of 0.75 equaled Temple Bar'saverage media sentiment score.

Company Overall Sentiment
International Biotechnology Positive
Temple Bar Positive

International Biotechnology pays an annual dividend of GBX 31.81 per share and has a dividend yield of 3.1%. Temple Bar pays an annual dividend of GBX 15.15 per share and has a dividend yield of 3.5%. International Biotechnology pays out 13.2% of its earnings in the form of a dividend. Temple Bar pays out 20.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

Temple Bar beats International Biotechnology on 8 of the 14 factors compared between the two stocks.

How does International Biotechnology compare to JPMorgan Japanese?

JPMorgan Japanese (LON:JFJ) and International Biotechnology (LON:IBT) are both small-cap finance companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

JPMorgan Japanese has higher revenue and earnings than International Biotechnology. International Biotechnology is trading at a lower price-to-earnings ratio than JPMorgan Japanese, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
JPMorgan Japanese£245.55M4.95£194.81M£149.065.48
International Biotechnology£78.01M4.12£37.91M£241.734.20

JPMorgan Japanese pays an annual dividend of GBX 8.70 per share and has a dividend yield of 1.1%. International Biotechnology pays an annual dividend of GBX 31.81 per share and has a dividend yield of 3.1%. JPMorgan Japanese pays out 5.8% of its earnings in the form of a dividend. International Biotechnology pays out 13.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

JPMorgan Japanese has a net margin of 96.52% compared to International Biotechnology's net margin of 82.27%. International Biotechnology's return on equity of 27.35% beat JPMorgan Japanese's return on equity.

Company Net Margins Return on Equity Return on Assets
JPMorgan Japanese96.52% 20.00% 8.06%
International Biotechnology 82.27%27.35%3.57%

18.9% of JPMorgan Japanese shares are held by institutional investors. Comparatively, 6.7% of International Biotechnology shares are held by institutional investors. 0.1% of JPMorgan Japanese shares are held by insiders. Comparatively, 1.1% of International Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

JPMorgan Japanese has a beta of 1.024, indicating that its share price is 2% more volatile than the broader market. Comparatively, International Biotechnology has a beta of 0.461, indicating that its share price is 54% less volatile than the broader market.

In the previous week, International Biotechnology had 1 more articles in the media than JPMorgan Japanese. MarketBeat recorded 1 mentions for International Biotechnology and 0 mentions for JPMorgan Japanese. International Biotechnology's average media sentiment score of 0.75 beat JPMorgan Japanese's score of 0.00 indicating that International Biotechnology is being referred to more favorably in the news media.

Company Overall Sentiment
JPMorgan Japanese Neutral
International Biotechnology Positive

Summary

JPMorgan Japanese beats International Biotechnology on 9 of the 15 factors compared between the two stocks.

How does International Biotechnology compare to IntegraFin?

International Biotechnology (LON:IBT) and IntegraFin (LON:IHP) are both small-cap finance companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

IntegraFin has higher revenue and earnings than International Biotechnology. International Biotechnology is trading at a lower price-to-earnings ratio than IntegraFin, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
International Biotechnology£78.01M4.12£37.91M£241.734.20
IntegraFin£165.40M7.30£52.54M£19.1019.14

In the previous week, IntegraFin had 4 more articles in the media than International Biotechnology. MarketBeat recorded 5 mentions for IntegraFin and 1 mentions for International Biotechnology. International Biotechnology's average media sentiment score of 0.75 beat IntegraFin's score of 0.36 indicating that International Biotechnology is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
International Biotechnology
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
IntegraFin
0 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

6.7% of International Biotechnology shares are held by institutional investors. Comparatively, 43.7% of IntegraFin shares are held by institutional investors. 1.1% of International Biotechnology shares are held by insiders. Comparatively, 14.5% of IntegraFin shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

International Biotechnology pays an annual dividend of GBX 31.81 per share and has a dividend yield of 3.1%. IntegraFin pays an annual dividend of GBX 11.30 per share and has a dividend yield of 3.1%. International Biotechnology pays out 13.2% of its earnings in the form of a dividend. IntegraFin pays out 59.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. International Biotechnology is clearly the better dividend stock, given its higher yield and lower payout ratio.

IntegraFin has a consensus target price of GBX 440, indicating a potential upside of 20.38%. Given IntegraFin's stronger consensus rating and higher probable upside, analysts plainly believe IntegraFin is more favorable than International Biotechnology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
International Biotechnology
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
IntegraFin
0 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.60

International Biotechnology has a net margin of 82.27% compared to IntegraFin's net margin of 28.60%. IntegraFin's return on equity of 27.60% beat International Biotechnology's return on equity.

Company Net Margins Return on Equity Return on Assets
International Biotechnology82.27% 27.35% 3.57%
IntegraFin 28.60%27.60%20.29%

International Biotechnology has a beta of 0.461, suggesting that its stock price is 54% less volatile than the broader market. Comparatively, IntegraFin has a beta of 1.276, suggesting that its stock price is 28% more volatile than the broader market.

Summary

IntegraFin beats International Biotechnology on 13 of the 18 factors compared between the two stocks.

How does International Biotechnology compare to Worldwide Healthcare?

Worldwide Healthcare (LON:WWH) and International Biotechnology (LON:IBT) are both small-cap finance companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Worldwide Healthcare has higher revenue and earnings than International Biotechnology. International Biotechnology is trading at a lower price-to-earnings ratio than Worldwide Healthcare, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Worldwide Healthcare£118.16M10.87£227.88M£26.7014.06
International Biotechnology£78.01M4.12£37.91M£241.734.20

Worldwide Healthcare has a net margin of 85.46% compared to International Biotechnology's net margin of 82.27%. International Biotechnology's return on equity of 27.35% beat Worldwide Healthcare's return on equity.

Company Net Margins Return on Equity Return on Assets
Worldwide Healthcare85.46% 8.01% -2.02%
International Biotechnology 82.27%27.35%3.57%

Worldwide Healthcare pays an annual dividend of GBX 2.40 per share and has a dividend yield of 0.6%. International Biotechnology pays an annual dividend of GBX 31.81 per share and has a dividend yield of 3.1%. Worldwide Healthcare pays out 9.0% of its earnings in the form of a dividend. International Biotechnology pays out 13.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

7.7% of Worldwide Healthcare shares are held by institutional investors. Comparatively, 6.7% of International Biotechnology shares are held by institutional investors. 0.2% of Worldwide Healthcare shares are held by insiders. Comparatively, 1.1% of International Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Worldwide Healthcare had 2 more articles in the media than International Biotechnology. MarketBeat recorded 3 mentions for Worldwide Healthcare and 1 mentions for International Biotechnology. Worldwide Healthcare's average media sentiment score of 1.62 beat International Biotechnology's score of 0.75 indicating that Worldwide Healthcare is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Worldwide Healthcare
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
International Biotechnology
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Worldwide Healthcare has a beta of 0.262, suggesting that its share price is 74% less volatile than the broader market. Comparatively, International Biotechnology has a beta of 0.461, suggesting that its share price is 54% less volatile than the broader market.

Summary

Worldwide Healthcare beats International Biotechnology on 9 of the 15 factors compared between the two stocks.

How does International Biotechnology compare to Molten Ventures?

Molten Ventures (LON:GROW) and International Biotechnology (LON:IBT) are both small-cap finance companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

International Biotechnology has lower revenue, but higher earnings than Molten Ventures. International Biotechnology is trading at a lower price-to-earnings ratio than Molten Ventures, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Molten Ventures£148M7.70-£33.58M£69.009.62
International Biotechnology£78.01M4.12£37.91M£241.734.20

Molten Ventures has a beta of 1.9564402, indicating that its share price is 96% more volatile than the broader market. Comparatively, International Biotechnology has a beta of 0.461, indicating that its share price is 54% less volatile than the broader market.

Molten Ventures currently has a consensus target price of GBX 638.67, suggesting a potential downside of 3.74%. Given Molten Ventures' stronger consensus rating and higher possible upside, analysts clearly believe Molten Ventures is more favorable than International Biotechnology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Molten Ventures
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
International Biotechnology
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

International Biotechnology has a net margin of 82.27% compared to Molten Ventures' net margin of 75.09%. International Biotechnology's return on equity of 27.35% beat Molten Ventures' return on equity.

Company Net Margins Return on Equity Return on Assets
Molten Ventures75.09% 9.21% -3.46%
International Biotechnology 82.27%27.35%3.57%

40.5% of Molten Ventures shares are owned by institutional investors. Comparatively, 6.7% of International Biotechnology shares are owned by institutional investors. 1.6% of Molten Ventures shares are owned by insiders. Comparatively, 1.1% of International Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, International Biotechnology had 1 more articles in the media than Molten Ventures. MarketBeat recorded 1 mentions for International Biotechnology and 0 mentions for Molten Ventures. International Biotechnology's average media sentiment score of 0.75 beat Molten Ventures' score of 0.00 indicating that International Biotechnology is being referred to more favorably in the news media.

Company Overall Sentiment
Molten Ventures Neutral
International Biotechnology Positive

Summary

Molten Ventures beats International Biotechnology on 9 of the 16 factors compared between the two stocks.

Get International Biotechnology News Delivered to You Automatically

Sign up to receive the latest news and ratings for IBT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IBT vs. The Competition

Export
MetricInternational BiotechnologyCapital Markets IndustryFinance SectorLON Exchange
Market Cap£321.28M£5.06B£13.46B£2.83B
Dividend Yield3.10%7.65%6.11%6.26%
P/E Ratio4.2027.9022.83366.80
Price / Sales4.121,189.48487.4688,717.76
Price / Cash155.7447.4742.3427.83
Price / Book1.323.462.716.85
Net Income£37.91M£415.07M£1.32B£5.88B
7 Day Performance-3.33%-0.65%-0.28%0.34%
1 Month Performance-8.14%-1.27%-1.92%-0.17%
1 Year Performance22.58%8.30%10.54%22.54%

International Biotechnology Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IBT
International Biotechnology
N/AGBX 1,015
-1.0%		N/A+24.4%£321.28M£78.01M4.20N/A
TMPL
Temple Bar
N/AGBX 413
+0.7%		N/A+18.7%£1.26B£222.42M5.49N/A
JFJ
JPMorgan Japanese
N/AGBX 833
+0.4%		N/A+17.1%£1.23B£245.55M5.59N/A
IHP
IntegraFin
3.6167 of 5 stars		GBX 378.50
+2.3%		GBX 435
+14.9%		+0.0%£1.22B£165.40M19.823,520
WWH
Worldwide Healthcare
N/AGBX 368
+2.8%		N/A+9.9%£1.22B£118.16M13.78N/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:IBT) was last updated on 10/16/2026 by MarketBeat.com Staff.
From Our Partners
I have publicly predicted six major American crashes, before each one happened.
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...
Weiss Ratings | Sponsoredtc pixel
Trump’s issues shocking Executive Order on U.S. Dollar
Three days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....
Banyan Hill Publishing | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Your Social Security check is scheduled for a 22% cut
The U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...
American Alternative | Sponsoredtc pixel
Undiscovered Sub-$1 Gold-Silver Royalty Stock Takes Flight
A small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...
Digest Publishing | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
A new income category is drawing serious money - here's why
Forbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...
Investors Alley | Sponsoredtc pixel
Buffett's Final Warning: "The Dollar Is Going to Hell"
Do not buy another AI stock until you've seen the arithmetic below. Nvidia is worth about $5.5 trillion. Al...
Decentralized Masters | Sponsoredtc pixel